Active substance
Cefditoren
- SFDA 2
- US FDA 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MEIACT 200 MG FILM COATED TABLETS | 200 mg | Film-coated tablet · Oral use | 20 Blister | SAR 79.70 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| MEIACT 400 MG FILM COATED TABLETS | 400 mg | Film-coated tablet · Oral use | 20 Blister | SAR 122.05 | NCE · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PYELONEPHRITIS; OSTEOMYELITIS; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SPECTRACEF | 200MG; 400MG | tablet · oral | VANSEN PHARMA | Discontinued | 29 Aug 2001 |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.